Helius Wagers $167 Million on Solana’s 7% Returns Instead of Bitcoin’s Idle Holdings

Helius Medical Technologies, Inc. (NASDAQ: HSDT) has committed $167 million to acquire

(SOL) tokens, representing a major move in its digital asset treasury approach. The company’s SOL holdings now exceed 760,190 , purchased at an average price of $231 each, as part of a larger plan to make SOL its main reserve asset. This investment comes after a heavily subscribed $500 million private investment in public equity (PIPE) round, which also included $750 million in attached warrants, potentially raising the total funding to $1.25 billion Helius (NASDAQ:HSDT) Begins Purchases of SOL, the Native Asset of Solana Blockchain [ 1 ]. The funds will be used for open-market SOL purchases and to develop a treasury strategy focused on staking and decentralized finance (DeFi) opportunities Solana DAT SZN: Helius Medical Technologies Raises $500M [ 2 ].

The financing was led by Pantera Capital and Summer Capital, with institutional backers including Big Brain Holdings, FalconX, and Animoca Brands Helius Medical Tech Jumps on Funding to Launch Solana Treasury [ 3 ]. Pantera Capital, a strategic partner, described Solana as the “most commercially viable blockchain” and pointed to its 7% native staking yield as a significant benefit compared to non-yielding assets like Bitcoin Helius Medical Bets Big on Solana with $500 Million Investment [ 4 ].

Medical’s leadership team, including Executive Chairman Joseph Chee (formerly of UBS) and Board Observer Cosmo Jiang (Pantera Capital), intends to capitalize on Solana’s high throughput (3,500 transactions per second) and its 3.7 million daily active wallets to achieve compounding returns Helius Medical Raises $500M for Solana Treasury Plan [ 5 ].

Solana’s robust financial performance and infrastructure have drawn institutional investors, with Helius joining companies like Forward Industries and DeFi Development Corp. in building substantial Solana treasuries. For instance, Forward Industries recently secured 6.82 million SOL at $232 each, amounting to $1.58 billion. Analysts highlight that Solana’s total value locked (TVL) in DeFi has surpassed $13 billion, ranking second only to

, and note that institutional investments are fueling the ecosystem’s expansion. Helius plans to increase its SOL reserves gradually over the next 12 to 24 months, maintaining a cautious risk approach and ensuring transparency with regular updates.

This strategy is part of a wider movement among public companies adopting digital asset treasuries to benefit from blockchain yields. Helius’s share price soared more than 140% after the news, echoing gains seen by other firms like BitMine following their crypto-focused initiatives. Nonetheless, this approach involves risks, including regulatory uncertainties and market fluctuations. The company has cautioned that forward-looking statements are subject to risks such as changes in regulations and SOL price volatility.

Helius Medical’s strategy aligns with Pantera Capital’s broader outlook for Solana as the “foundation of a new financial system.” Pantera’s existing $1.1 billion Solana position highlights its confidence in the blockchain’s scalability and efficiency. With cash reserves exceeding $335 million, Helius aims to balance its neurotechnology business with strategic digital asset investments, positioning itself as a leading institutional player in the Solana ecosystem.